Literature DB >> 17183142

Optimum parameters in a model for tumour control probability, including interpatient heterogeneity: evaluation of the log-normal distribution.

P J Keall1, S Webb.   

Abstract

The heterogeneity of human tumour radiation response is well known. Researchers have used the normal distribution to describe interpatient tumour radiosensitivity. However, many natural phenomena show a log-normal distribution. Log-normal distributions are common when mean values are low, variances are large and values cannot be negative. These conditions apply to radiosensitivity. The aim of this work was to evaluate the log-normal distribution to predict clinical tumour control probability (TCP) data and to compare the results with the homogeneous (delta-function with single alpha-value) and normal distributions. The clinically derived TCP data for four tumour types-melanoma, breast, squamous cell carcinoma and nodes-were used to fit the TCP models. Three forms of interpatient tumour radiosensitivity were considered: the log-normal, normal and delta-function. The free parameters in the models were the radiosensitivity mean, standard deviation and clonogenic cell density. The evaluation metric was the deviance of the maximum likelihood estimation of the fit of the TCP calculated using the predicted parameters to the clinical data. We conclude that (1) the log-normal and normal distributions of interpatient tumour radiosensitivity heterogeneity more closely describe clinical TCP data than a single radiosensitivity value and (2) the log-normal distribution has some theoretical and practical advantages over the normal distribution. Further work is needed to test these models on higher quality clinical outcome datasets.

Entities:  

Mesh:

Year:  2006        PMID: 17183142     DOI: 10.1088/0031-9155/52/1/019

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  4 in total

Review 1.  Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy.

Authors:  Tejan P Diwanji; Pranshu Mohindra; Melissa Vyfhuis; James W Snider; Chaitanya Kalavagunta; Sina Mossahebi; Jen Yu; Steven Feigenberg; Shahed N Badiyan
Journal:  Transl Lung Cancer Res       Date:  2017-04

2.  Evaluation of the deformation and corresponding dosimetric implications in prostate cancer treatment.

Authors:  Ning Wen; Carri Glide-Hurst; Teamour Nurushev; Lei Xing; Jinkoo Kim; Hualiang Zhong; Dezhi Liu; Manju Liu; Jay Burmeister; Benjamin Movsas; Indrin J Chetty
Journal:  Phys Med Biol       Date:  2012-08-03       Impact factor: 3.609

3.  Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRI.

Authors:  E J Her; A Haworth; H M Reynolds; Y Sun; A Kennedy; V Panettieri; M Bangert; S Williams; M A Ebert
Journal:  Radiat Oncol       Date:  2020-07-13       Impact factor: 3.481

Review 4.  In silico modelling of treatment-induced tumour cell kill: developments and advances.

Authors:  Loredana G Marcu; Wendy M Harriss-Phillips
Journal:  Comput Math Methods Med       Date:  2012-07-12       Impact factor: 2.238

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.